source
- Roche partners with Simcere Zaiming on trispecific T cell engager, $75M upfrontRoche announced a collaboration with Chinese biopharma Simcere Zaiming to develop a trispecific T cell engager aimed at cancer therapy. The agreement includes an upfront payment of $75 million to…
- Arsenal Biosciences cuts 99 jobs as it pivots to in-vivo CAR-T therapyArsenal Biosciences announced a major restructuring, laying off 99 employees, which represents the majority of its workforce across all teams and locations. The company is ending development of it…